Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.

Roksnoer LC, van Veghel R, van Groningen MC, de Vries R, Garrelds IM, Bhaggoe UM, van Gool JM, Friesema EC, Leijten FP, Hoorn EJ, Danser AH, Batenburg WW.

Clin Sci (Lond). 2016 Jul 1;130(14):1209-20. doi: 10.1042/CS20160197. Epub 2016 Apr 19.

PMID:
27129187
2.

On the Origin of Urinary Renin: A Translational Approach.

Roksnoer LC, Heijnen BF, Nakano D, Peti-Peterdi J, Walsh SB, Garrelds IM, van Gool JM, Zietse R, Struijker-Boudier HA, Hoorn EJ, Danser AH.

Hypertension. 2016 May;67(5):927-33. doi: 10.1161/HYPERTENSIONAHA.115.07012. Epub 2016 Feb 29.

3.

Human fear acquisition deficits in relation to genetic variants of the corticotropin-releasing hormone receptor 1 and the serotonin transporter--revisited.

Heitland I, Groenink L, van Gool JM, Domschke K, Reif A, Baas JM.

Genes Brain Behav. 2016 Feb;15(2):209-20. doi: 10.1111/gbb.12276. Epub 2016 Jan 18.

4.

Methodologic issues in the measurement of urinary renin.

Roksnoer LC, Verdonk K, Garrelds IM, van Gool JM, Zietse R, Hoorn EJ, Danser AH.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1163-7. doi: 10.2215/CJN.12661213. Epub 2014 Apr 17.

5.

Neuron-specific (pro)renin receptor knockout prevents the development of salt-sensitive hypertension.

Li W, Peng H, Mehaffey EP, Kimball CD, Grobe JL, van Gool JM, Sullivan MN, Earley S, Danser AH, Ichihara A, Feng Y.

Hypertension. 2014 Feb;63(2):316-23. doi: 10.1161/HYPERTENSIONAHA.113.02041. Epub 2013 Nov 18.

6.

New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin.

Krop M, Lu X, Verdonk K, Schalekamp MA, van Gool JM, McKeever BM, Gregg R, Danser AH.

Hypertension. 2013 May;61(5):1075-82. doi: 10.1161/HYPERTENSIONAHA.111.00967. Epub 2013 Mar 4.

PMID:
23460288
7.

Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.

van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, van den Meiracker AH, Danser AH.

J Hypertens. 2011 Nov;29(11):2147-55. doi: 10.1097/HJH.0b013e32834bbcbf.

PMID:
21941204
8.

Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment.

Krop M, van Gool JM, Day D, Hollenberg NK, Jan Danser AH.

J Hypertens. 2011 Nov;29(11):2138-46. doi: 10.1097/HJH.0b013e32834b1978.

PMID:
21881521
9.

Cardiac Renin levels are not influenced by the amount of resident mast cells.

Krop M, van Veghel R, Garrelds IM, de Bruin RJ, van Gool JM, van den Meiracker AH, Thio M, van Daele PL, Danser AH.

Hypertension. 2009 Aug;54(2):315-21. doi: 10.1161/HYPERTENSIONAHA.109.133892. Epub 2009 Jun 29.

PMID:
19564544
10.

Aliskiren accumulates in Renin secretory granules and binds plasma prorenin.

Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, Jan Danser AH.

Hypertension. 2008 Dec;52(6):1076-83. doi: 10.1161/HYPERTENSIONAHA.108.123042. Epub 2008 Nov 3.

PMID:
18981317
11.

Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells.

Batenburg WW, de Bruin RJ, van Gool JM, Müller DN, Bader M, Nguyen G, Danser AH.

Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1151-7. doi: 10.1161/ATVBAHA.108.164210. Epub 2008 Apr 3.

PMID:
18388329
12.

Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.

van Esch JH, van Gool JM, de Bruin RJ, Payne JR, Montgomery HE, Hectors M, Deinum J, Dive V, Jan Danser AH.

J Hypertens. 2008 Apr;26(4):706-13. doi: 10.1097/HJH.0b013e3282f465d2.

PMID:
18327080
13.

Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.

van Esch JH, Tom B, Dive V, Batenburg WW, Georgiadis D, Yiotakis A, van Gool JM, de Bruijn RJ, de Vries R, Danser AH.

Hypertension. 2005 Jan;45(1):120-5. Epub 2004 Dec 6.

PMID:
15583077
14.

Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy.

Deinum J, van Gool JM, Kofflard MJ, ten Cate FJ, Danser AH.

Hypertension. 2001 Dec 1;38(6):1278-81.

PMID:
11751703
15.

Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy.

Deinum J, Tarnow L, van Gool JM, de Bruin RA, Derkx FH, Schalekamp MA, Parving HH.

Nephrol Dial Transplant. 1999 Aug;14(8):1904-11.

PMID:
10462269
16.

Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity.

Derkx FH, de Bruin RJ, van Gool JM, van den Hoek MJ, Beerendonk CC, Rosmalen F, Haima P, Schalekamp MA.

Clin Chem. 1996 Jul;42(7):1051-63.

17.

A novel assay of plasma prorenin using a renin inhibitor.

Derkx FH, de Bruin RJ, van Gool JM, Rosmalen FM, van Hoek MJ, Beerendonk CC, Schalekamp MA.

J Hypertens Suppl. 1993 Dec;11(5):S240-1. No abstract available.

PMID:
8158364

Supplemental Content

Loading ...
Support Center